These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

287 related articles for article (PubMed ID: 21402292)

  • 21. Cost-effectiveness of novel therapies for overactive bladder.
    Mayr CA; Shepherd JP
    Expert Rev Pharmacoecon Outcomes Res; 2014 Aug; 14(4):527-35. PubMed ID: 24809616
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Refractory overactive bladder after urethrolysis for bladder outlet obstruction: management with sacral neuromodulation.
    Starkman JS; Duffy JW; Wolter CE; Kaufman MR; Scarpero HM; Dmochowski RR
    Int Urogynecol J Pelvic Floor Dysfunct; 2008 Feb; 19(2):277-82. PubMed ID: 17671752
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A prospective, multicenter study of a novel, miniaturized rechargeable sacral neuromodulation system: 12-month results from the RELAX-OAB study.
    Blok B; Van Kerrebroeck P; de Wachter S; Ruffion A; Van der Aa F; Jairam R; Perrouin-Verbe MA; Elneil S
    Neurourol Urodyn; 2019 Feb; 38(2):689-695. PubMed ID: 30592526
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cost-effectiveness of sacral neuromodulation versus intravesical botulinum A toxin for treatment of refractory urge incontinence.
    Siddiqui NY; Amundsen CL; Visco AG; Myers ER; Wu JM
    J Urol; 2009 Dec; 182(6):2799-804. PubMed ID: 19837427
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cost-effectiveness analysis of sacral neuromodulation for faecal incontinence in The Netherlands.
    van Wunnik BP; Visschers RG; van Asselt AD; Baeten CG
    Colorectal Dis; 2012 Dec; 14(12):e807-14. PubMed ID: 22943485
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Refractory overactive bladder patients who chose sacral neuromodulation therapy after failed OnabotulinumtoxinA treatment: A systematic review and meta-analysis.
    Yang G; Xu Y; Qu G; Zhang Y
    PLoS One; 2020; 15(3):e0230355. PubMed ID: 32226049
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Results of a prospective, randomized, multicenter study evaluating sacral neuromodulation with InterStim therapy compared to standard medical therapy at 6-months in subjects with mild symptoms of overactive bladder.
    Siegel S; Noblett K; Mangel J; Griebling TL; Sutherland SE; Bird ET; Comiter C; Culkin D; Bennett J; Zylstra S; Berg KC; Kan F; Irwin CP
    Neurourol Urodyn; 2015 Mar; 34(3):224-30. PubMed ID: 24415559
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The management of overactive bladder: percutaneous tibial nerve stimulation, sacral nerve stimulation, or botulinum toxin?
    Tubaro A; Puccini F; De Nunzio C
    Curr Opin Urol; 2015 Jul; 25(4):305-10. PubMed ID: 26049873
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy and tolerance of botulinum toxin injections after sacral nerve stimulation failure for idiopathic overactive bladder.
    Baron M; Perrouin-Verbe MA; Lacombe S; Paret F; Le Normand L; Cornu JN
    Neurourol Urodyn; 2020 Mar; 39(3):1012-1019. PubMed ID: 32108383
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A cost-effectiveness analysis of Onabotulinumtoxin A as first-line treatment for overactive bladder.
    Shepherd JP; Carter-Brooks CM; Chermanksy C
    Int Urogynecol J; 2018 Aug; 29(8):1213-1219. PubMed ID: 29671033
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cost-Effectiveness of Sacral Neuromodulation versus OnabotulinumtoxinA for Refractory Urgency Urinary Incontinence: Results of the ROSETTA Randomized Trial.
    Harvie HS; Amundsen CL; Neuwahl SJ; Honeycutt AA; Lukacz ES; Sung VW; Rogers RG; Ellington D; Ferrando CA; Chermansky CJ; Mazloomdoost D; Thomas S
    J Urol; 2020 May; 203(5):969-977. PubMed ID: 31738113
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacotherapy for overactive bladder: minimally invasive treatment -- botulinum toxins.
    Apostolidis A
    Expert Opin Pharmacother; 2011 May; 12(7):1029-39. PubMed ID: 21288184
    [TBL] [Abstract][Full Text] [Related]  

  • 33. To stage or not to stage?-A cost minimization analysis of sacral neuromodulation placement strategies.
    Sun AJ; Harris CR; Comiter CV; Elliott CS
    Neurourol Urodyn; 2019 Aug; 38(6):1783-1791. PubMed ID: 31215706
    [TBL] [Abstract][Full Text] [Related]  

  • 34. OnabotulinumtoxinA in the treatment of overactive bladder: a cost-effectiveness analysis versus best supportive care in England and Wales.
    Freemantle N; Khalaf K; Loveman C; Stanisic S; Gultyaev D; Lister J; Drake M
    Eur J Health Econ; 2016 Sep; 17(7):911-21. PubMed ID: 26482712
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Sacral neuromodulation for the treatment of fecal incontinence: analysis of cost-effectiveness.
    Indinnimeo M; Ratto C; Moschella CM; Fiore A; Brosa M; Giardina S
    Dis Colon Rectum; 2010 Dec; 53(12):1661-9. PubMed ID: 21178862
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prolonged percutaneous SNM testing does not cause infection-related explanation.
    Amend B; Bedke J; Khalil M; Stenzl A; Sievert KD
    BJU Int; 2013 Mar; 111(3):485-91. PubMed ID: 22738331
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cost effectiveness analysis of fesoterodine compared to mirabegron in first-line therapy setting for overactive bladder with urge urinary incontinence, from the Spanish National Health System perspective.
    Angulo JC; Sánchez-Ballester F; Peral C; Rejas J; Ramos J; Snedecor SJ; Sudharshan L; Liu S; Luo X
    Actas Urol Esp; 2016 Oct; 40(8):513-22. PubMed ID: 26988624
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Outcomes of sequential third-line therapies in patients with refractory overactive bladder.
    Chow PM; Trump T; Goldman HB
    Int J Urol; 2024 Jul; 31(7):772-777. PubMed ID: 38693892
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cost of neuromodulation therapies for overactive bladder: percutaneous tibial nerve stimulation versus sacral nerve stimulation.
    Martinson M; MacDiarmid S; Black E
    J Urol; 2013 Jan; 189(1):210-6. PubMed ID: 23174264
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Two-Year Outcomes of Sacral Neuromodulation Versus OnabotulinumtoxinA for Refractory Urgency Urinary Incontinence: A Randomized Trial.
    Amundsen CL; Komesu YM; Chermansky C; Gregory WT; Myers DL; Honeycutt EF; Vasavada SP; Nguyen JN; Wilson TS; Harvie HS; Wallace D;
    Eur Urol; 2018 Jul; 74(1):66-73. PubMed ID: 29482936
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.